Haplotype structure and selection of the MDM2 oncogene in humans
- PMID: 17360557
- PMCID: PMC1838634
- DOI: 10.1073/pnas.0610998104
Haplotype structure and selection of the MDM2 oncogene in humans
Abstract
The MDM2 protein is an ubiquitin ligase that plays a critical role in regulating the levels and activity of the p53 protein, which is a central tumor suppressor. A SNP in the human MDM2 gene (SNP309 T/G) occurs at frequencies dependent on demographic history and has been shown to have important differential effects on the activity of the MDM2 and p53 proteins and to associate with altered risk for the development of several cancers. In this report, the haplotype structure of the MDM2 gene is determined by using 14 different SNPs across the gene from three different population samples: Caucasians, African Americans, and the Ashkenazi Jewish ethnic group. The results presented in this report indicate that there is a substantially reduced variability of the deleterious SNP309 G allele haplotype in all three populations studied, whereas multiple common T allele haplotypes were found in all three populations. This observation, coupled with the relatively high frequency of the G allele haplotype in both and Caucasian and Ashkenazi Jewish population data sets, suggests that this haplotype could have undergone a recent positive selection sweep. An entropy-based selection test is presented that explicitly takes into account the correlations between different SNPs, and the analysis of MDM2 reveals a significant departure from the standard assumptions of selective neutrality.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
Identification of functional DNA variants in the constitutive promoter region of MDM2.Hum Genomics. 2012 Sep 1;6(1):15. doi: 10.1186/1479-7364-6-15. Hum Genomics. 2012. PMID: 23244604 Free PMC article.
-
Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis.Gene. 2021 Aug 15;793:145747. doi: 10.1016/j.gene.2021.145747. Epub 2021 May 30. Gene. 2021. PMID: 34077778
-
MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.Breast Cancer Res Treat. 2008 Oct;111(3):497-504. doi: 10.1007/s10549-007-9797-z. Epub 2007 Nov 18. Breast Cancer Res Treat. 2008. PMID: 18026875
-
Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations.BMC Cancer. 2009 Feb 18;9:60. doi: 10.1186/1471-2407-9-60. BMC Cancer. 2009. PMID: 19226467 Free PMC article.
-
The Role of MDM2 Amplification and Overexpression in Tumorigenesis.Cold Spring Harb Perspect Med. 2016 Jun 1;6(6):a026336. doi: 10.1101/cshperspect.a026336. Cold Spring Harb Perspect Med. 2016. PMID: 27194168 Free PMC article. Review.
Cited by
-
A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models.Elife. 2018 Mar 20;7:e34701. doi: 10.7554/eLife.34701. Elife. 2018. PMID: 29557783 Free PMC article.
-
Differential regulation of antagonistic pleiotropy in synthetic and natural populations suggests its role in adaptation.G3 (Bethesda). 2015 Feb 23;5(5):699-709. doi: 10.1534/g3.115.017020. G3 (Bethesda). 2015. PMID: 25711830 Free PMC article.
-
Polymorphisms in promoter sequences of MDM2, p53, and p16 genes in normal Japanese individuals.Genet Mol Biol. 2010 Oct;33(4):615-26. doi: 10.1590/s1415-47572010000400004. Epub 2010 Dec 1. Genet Mol Biol. 2010. PMID: 21637567 Free PMC article.
-
Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia.Am J Hum Genet. 2009 Apr;84(4):534-41. doi: 10.1016/j.ajhg.2009.03.009. Epub 2009 Apr 2. Am J Hum Genet. 2009. PMID: 19344876 Free PMC article.
-
Polymorphism of genes and implantation failure.Int J Mol Cell Med. 2013 Winter;2(1):1-8. Int J Mol Cell Med. 2013. PMID: 24551783 Free PMC article. Review.
References
-
- Jin S, Levine AJ. J Cell Sci. 2001;114:4139–4140. - PubMed
-
- Lain S, Lane D. Eur J Cancer. 2003;39:1053–1060. - PubMed
-
- Bond GL, Hu W, Levine AJ. Curr Cancer Drug Targets. 2005;5:3–8. - PubMed
-
- Murphy ME. Cell Death Differ. 2006;13:916–920. - PubMed
-
- Bonafe M, Salvioli S, Barbi C, Mishto M, Trapassi C, Gemelli C, Storci G, Olivieri F, Monti D, Franceschi C. Biochem Biophys Res Commun. 2002;299:539–541. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous